From the earliest days of COVID-19, King & Spalding has been at the forefront of vaccine developments, helping our leading pharmaceutical clients develop and implement strategies to contain the legal and reputational risks throughout their journey.  At this critical juncture of distribution, our COVID-19 Vaccine Rollout Task Force is drawing on our industry knowledge and client relationships to serve as a guiding light and partner to our clients.  

As you will see in the resources herein, we are focused on untangling the matrix of hurdles that arise in this unchartered landscape of developing state guidance intersecting with a rapidly evolving federal landscape.  We are also examining the legislation developing to advise clients on immunity provisions and helping our clients prepare for potential investigations and litigation to follow. 

Back to COVID-19 Vaccine Rollout